What is Epocrates?
Epocrates serves as a foundational platform for clinical intelligence, offering a suite of practice tools designed to enhance physician efficiency and patient outcomes. By integrating complex medical data into a user-friendly mobile and desktop interface, the company addresses the critical need for real-time information at the point of care. Its market position is defined by its deep penetration within the U.S. physician community, where it acts as a trusted intermediary for drug information, clinical guidelines, and health industry engagement.
As an athenahealth service, Epocrates benefits from broader enterprise-level synergies, allowing it to scale its reach and deepen its integration within clinical workflows. The company remains a primary resource for practitioners seeking to reduce diagnostic uncertainty and streamline administrative burdens, thereby reinforcing its role as an indispensable asset in the digital transformation of healthcare delivery.
How much funding has Epocrates raised?
Epocrates has raised a total of $138M across 4 funding rounds:
Series A
$10.8M
Series B
$35M
Series C
$6.4M
Stock Offering
$85.8M
Series A (1999): $10.8M, investors not publicly disclosed
Series B (2000): $35M led by Three Arch Partners, Draper Fisher Jurvetson (DFJ), InterWest Partners, Bay City Capital, and Sprout Group
Series C (2002): $6.4M supported by Bay City Capital, Draper Fisher Jurvetson (DFJ), Three Arch Partners, Sprout Group, and InterWest Partners
Stock Issuance/Offering (2011): $85.8M, investors not publicly disclosed
Key Investors in Epocrates
Draper Fisher Jurvetson (DFJ)
A prominent venture capital firm with a global footprint, DFJ focuses on backing extraordinary entrepreneurs across various sectors, including significant catalysts in the healthcare and technology industries.
Three Arch Partners
A specialized healthcare investment firm that provides young companies with access to clinical resources and capital, focusing on medical devices and healthcare services.
Bay City Capital
A venture capital firm established in 1997 that specializes in the life sciences sector, supporting innovative companies through significant clinical and therapeutic milestones.
What's next for Epocrates?
Looking ahead, the strategic focus for Epocrates involves deepening its integration within the broader athenahealth ecosystem to drive further value for healthcare providers. With the foundation provided by its historical capital raises, the company is well-positioned to expand its clinical intelligence capabilities, potentially incorporating advanced analytics and predictive modeling to further support evidence-based medicine.
The firm's future growth will likely center on enhancing interoperability between its mobile tools and electronic health record systems, ensuring that clinical insights are not only accessible but actionable within the physician's existing workflow. By continuing to prioritize the needs of the clinician, Epocrates aims to solidify its leadership in the competitive health-tech sector, leveraging its established user base to drive innovation in point-of-care technology.
